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SUMMARY 
Pubertal induction in girls with ovarian insufficiency aims to mimic normal puberty, a 
highly complex process. Here we amalgamate the sparse global evidence and 
propose three options for pubertal induction regimens including oral 
ethinyloestradiol, and oral and transdermal 17β-oestradiol. The introduction of 
progestogens is discussed and the transition to hormone supplementation for adult 
women. The merits and disadvantages of the different options are detailed. The 
available evidence indicates that transdermal 17β-oestradiol has the most favourable 
efficacy, safety, and cost profile but randomised controlled trials are urgently 
required to determine which regimen provides the best clinical outcomes. 
INTRODUCTION 
Girls with primary or secondary ovarian insufficiency require supplementation with 
oestrogen to induce puberty. However, there are no licensed hormone preparations 
for children, resulting in off-label prescribing of formulations licensed for adults. 
Traditionally, most clinicians in the UK have used low dose synthetic 
ethinyloestradiol with variable clinical outcomes.[1] More recently, the escalating 
cost, poor availability and unfavourable outcomes associated with low dose 
ethinyloestradiol has necessitated the use of alternatives. In continental Europe and 
USA, there is greater experience of using natural transdermal or oral 17β-
oestradiol.[2] Following critical review of the available literature and extensive 
consultation by a working group of the British Paediatric Endocrine Society (BSPED), 
this guidance document for pubertal induction has been produced. The document 
provides the full range of therapeutic options including oral and transdermal 17β-
oestradiol and oral ethinyloestradiol. 
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Pubertal induction aims to achieve normal tempo and magnitude of breast and 
uterine development and adolescent growth spurt by mimicking the natural pubertal 
process. These outcomes are achieved with low starting doses of oestrogen which 
are then gradually increased, whilst monitoring the clinical response in linear growth 
and breast staging. High dose oestrogen early in puberty or rapid dose escalation 
may result in reduced final height and poor breast development, such as prominent 
nipple development with poor supporting breast tissue. There are also concerns that 
unphysiological supplementation may adversely affect uterine development and 
bone mass accrual.[3] 
Girls are known to prefer progress in tandem with their peers. Therefore, the 
recommended age for commencing pubertal induction is around 11-12 years, 
although some girls may actually present much later. 
The aims of pubertal induction are to:- 
• Allow the natural development of secondary sexual characteristics 
(particularly breast shape and size). 
• Allow normal uterine growth to an adult size and shape. 
• Achieve a good adolescent growth spurt. 
• Achieve normal peak bone mass. 
• Support psychological maturation and adjustment.  
 
LITERATURE REVIEW 
There is a real paucity of carefully constructed, randomised controlled clinical trials in 
girls undergoing induction of puberty. The evidence base is derived mainly from 
Page 4 of 26
https://mc.manuscriptcentral.com/adc
Archives of Disease in Childhood
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
 
expert experience, a small number of observational studies and very few controlled 
trials on small study populations. In addition, studies of treatment acceptability and 
patient adherence are lacking. 
 
Transdermal/Oral 17β-oestradiol for Induction of Puberty 
17β-oestradiol is the most physiological form of oestrogen, being identical to ovarian 
secreted oestrogen and measurable in serum. Whilst oral 17β-oestradiol is 
metabolized in the liver to the weaker oestrogen oestrone, transdermal 17β-
oestradiol does not undergo this first-pass effect. The available evidence on the use 
of 17β-oestradiol is sparse on all clinical outcomes mentioned above. 
Transdermal 17β-oestradiol 
Three regimens using transdermal 17β-oestradiol were reviewed. In a carefully 
monitored observational study, Ankarberg-Lindgren et al., used a low dose 
transdermal 17β-oestradiol regimen in 15 girls with primary ovarian insufficiency 
(POI) which resulted in pubertal development to breast stage 2-3 (B2-3) over a 
period of 3.5-29 months (median 10 months).[4] However, this dosing regimen was 
based on body weight with complicated cutting of patches into small fractions and 
did not extend beyond early to mid-puberty. Davenport provided a regimen for 
pubertal induction in girls with Turner syndrome basing transdermal 17β-oestradiol 
dose on body weight in early puberty, and adjusting patch size to target serum 
oestradiol levels.[5] Nabhan et al. used much higher doses of transdermal 17β-
oestradiol starting with 25µg/24hrs.[6] 
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There is very limited but encouraging evidence on breast development [7], uterine 
growth [8, 9] and bone accrual [10] in females treated with transdermal 17β-
oestradiol. Because of its mode of administration, transdermal 17β-oestradiol does 
not lower IGF-1 levels since there is no effect on hepatic metabolism.[11] Therefore, 
it might enhance linear growth although this has not been studied to date.[8] 
 
Oral 17β-oestradiol 
Four regimens using oral 17β-oestradiol for pubertal induction were reviewed. 
Zacharin used a starting dose of 0.5mg 17β-oestradiol every second day, increasing 
doses over 2 years to an adult dose of 2mgs daily.[12] Delemarre et al.[13] and 
Bannink et al.[14] based 17β-oestradiol dose on body weight, starting with 
5µg/kg/day and increasing to an adult dose over 2 and 3 years respectively. Labarta 
et al. used 0.2mg 17β-oestradiol daily for one year, followed by 0.5mgs daily for the 
second year.[15] 
In terms of clinical outcomes, Bannink et al. treated 56 girls with Turner syndrome 
with incremental oral 17β-oestradiol and described normal breast development up to 
B4-5 in 49 girls (87%).[14] Labarta et al. treated 48 girls with Turner syndrome over 2 
years using individualised or fixed dose 17β-oestradiol and described breast 
development to B4 in 42% and 65% of girls respectively.[15] The results from studies 
looking at uterine growth are variable.[14, 16, 17] Torres-Santiago et al. found 
significant but similar improvements in whole-body and lumbar BMD Z-scores over 
12 months in 40 girls with Turner syndrome randomised to either oral or transdermal 
17β-oestradiol.[18]  
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Dose titration against serum oestradiol levels 
An ultrasensitive assay may be used to monitor serum 17β-oestradiol concentrations 
in early puberty for both transdermal and oral 17β-oestradiol induction regimens. 
These results may assist in adjusting doses of oestradiol aiming for serum 
concentrations in the early pubertal range (10-40pmols/L).[4] Ankarberg-Lindgren et 
al. showed that standard doses of transdermal oestradiol based on body weight 
resulted in considerable inter-individual variation in serum 17β-oestradiol 
concentrations highlighting the clinical value of using serum levels to guide dosing 
regimens.[19] Conversely, the conclusion from Bannink’s low-dose oral 17β-
oestradiol study was that serum oestradiol concentrations do not provide additional 
information on the progression through puberty.[14] For those girls completing 
puberty, a pharmacokinetic and pharmacodynamic study of oral and 
transdermal17β-oestradiol in girls with Turner syndrome suggested an adult target 
17β-oestradiol concentration of 350pmol/l, as derived from healthy menstruating 
adult women using integrated mean levels over the natural cycle.[20] 
 
Oral Ethinyloestradiol for Induction of Puberty 
Three published regimens for pubertal induction using ethinyloestradiol were 
reviewed.[13, 21, 22] These regimens share a gradual increase in ethinyloestradiol 
dose, either from a starting dose of 2µg daily [22] or 0.1 µg/kg/d [13, 21] followed by 
the addition of a progestogen after 2-2.5 years of unopposed oestrogen.  
Ethinyloestradiol is synthetic, cannot be measured in serum, and undergoes first-
pass metabolism in the liver. Similar to 17β-oestradiol, published data regarding the 
clinical efficacy of oral ethinyloestradiol in pubertal induction are very limited. 
Page 7 of 26
https://mc.manuscriptcentral.com/adc
Archives of Disease in Childhood
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
 
Suboptimal breast development is reported in girls treated with ethinyloestradiol and 
oestradiol valerate.[23, 24] However, it is unclear whether this is secondary to 
problems with the formulation, dose effect, rate of dose escalation or timing of start 
of therapy.[23] One study of 38 girls treated with incremental oral ethinyloestradiol 
showed that only 50% developed mature, heart-shaped uterine configurations.[24] 
Similarly, another study suggested that replacement therapy with ethinyloestradiol 
gave rise to poor uterine growth and development.[3] 
Few studies assessed the effect of ethinyloestradiol on bone mass accrual and there 
are significant pitfalls in the interpretation of dual energy X-ray absorptiometry results 
of children and adults with short stature such as in Turner syndrome.[25] A 
randomised crossover trial in 18 young women with POI showed no significant 
change in lumbar spine BMD z-score following ethinyloestradiol treatment, raising 
concerns that this agent may not be effective in increasing bone mass.[10] Another 
randomised crossover study in 17 young women with Turner Syndrome 
demonstrated that ethinyloestradiol treatment was associated with high urinary 
deoxypyridinoline cross-link concentrations, suggesting an unfavourable effect on 
bone turnover.[26] 
Oral ethinyloestradiol is associated with lower IGF-1 concentrations due to its first 
pass hepatic effect although no studies have compared growth rates and final height 
using different female hormone replacement strategies. A small synergistic effect on 
final height was found between low dose childhood ethinyloestradiol and growth 
hormone treatment in girls with Turner syndrome.[21] 
 
Introduction of Progestogens during Late Puberty 
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Much of the literature considers the role of oestrogen in pubertal induction with little 
discussion about the regimen, timing and choice of progestogens.  
Progestogens are usually introduced after a suitable duration of unopposed 
oestrogen (2-3 years) or if more than one episode of significant breakthrough 
bleeding occurs. Progestogens are usually given in 12-14 day blocks, each inducing 
withdrawal bleeding. The frequency of blocks may be adjusted according to the 
patient’s wishes, but at least every 2-3 months, which avoids endometrial 
hypertrophy. Introducing a progestogen too soon, especially using one of the more 
androgenic agents such as norethisterone, may potentially compromise uterine 
growth and development.[3]  
Options for treatment include oral Utrogestan (200mg once daily) or oral 
Medroxyprogesterone acetate (5mg once daily). Utrogestan is a natural micronized 
progesterone which can be given orally and gives good cycle control without 
significant side effects. Medroxyprogesterone acetate is a synthetic derivative of 
17α-hydroxyprogesterone and is less androgenic than derivatives of 19-
nortestosterone such as norethisterone.[27] 
 
Oestrogen and Progestogen Replacement Therapy in Adult Women 
Adolescent girls undergoing pubertal induction require adult regimens at the end of 
puberty. Similar to children and adolescents, no product is designed for long term 
use in women with POI. Options include oral 17β-oestradiol, transdermal 17β-
oestradiol, the combined oral contraceptive pill (COCP) and equine conjugated 
oestrogens (popular in the USA). Typical daily adult regimens for these preparations 
are oral 17β-oestradiol 2mg daily, transdermal 17β-oestradiol 50-100µg patches 
Page 9 of 26
https://mc.manuscriptcentral.com/adc
Archives of Disease in Childhood
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
 
applied twice weekly and left in place until replaced, and COCP daily containing 20-
30µg of ethinyloestradiol. 
In adult women, progestogen may be given cyclically or continuously depending on 
whether women wish to experience withdrawal bleeds. Oral progestogens are 
available either as single agents (e.g. Provera®) or in user-friendly combined packs 
(e.g. Elleste-Duet®, Elleste-Duet Conti®) or as the COCP (e.g. Microgynon®, 
Marvelon®). Combined transdermal patches with 17β-oestradiol and progestogen 
are available, e.g. Evorel Sequi® & Evorel Conti®. However, breakthrough bleeding 
may be more common in young women using transdermal progestogens. 
 
Unfavourable cardiovascular risk of ethinyloestradiol/COCP 
The COCP is cheap (free via the NHS in the UK) and readily available. However, if 
taken as prescribed on a monthly cycle, women with POI lack oestrogen 
supplementation 1 in 4 weeks. In addition, the COCP has an adverse cardiovascular 
and metabolic profile. Specifically, the addition of th  ethinyl side chain in 
ethinyloestradiol induces renin substrate  at a much greater rate than natural 
products and  increases the risk of hypertension, particularly in susceptible groups 
such as women with Turner syndrome.[28] Use of the COCP is also linked with an 
increased risk of venous thromboembolism.[29] Metabolic studies in adults suggest 
that ethinyloestradiol treatment gives rise to increased SHBG, decreased IGF-1 and 
increased insulin resistance.[11] In addition, C-reactive protein and other acute 
phase reactants may increase which independently predict cardiovascular 
disease.[30]  
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Studies comparing transdermal 17β-oestradiol with the COCP demonstrate reduced 
blood pressure, better renal function and less activation of the renin-angiotensin 
system in women using 17β-oestradiol.[31]  
Women with POI are a heterogeneous group with different risk profiles. Women with 
Turner syndrome seem to have a reduced risk of breast cancer (relative risk 0.3) 
whereas women who have had whole body irradiation as conditioning for bone 
marrow transplantation have an increased risk (relative risk 6.5).[32, 33] Both groups 
of women are at greater risk of hypertension and Type 2 diabetes than their normal 
peers and their choice of oestrogen replacement therapy needs to minimise these 
risks. Women who have had cranial irradiation for brain tumours have an increased 
risk of stroke and treatment with transdermal 17β-oestradiol is preferred.[34] 
 
Summary of Literature Review 
In summary, pubertal induction using oral or transdermal17β-oestradiol is well 
described but there is some concern regarding appropriate starting doses and inter-
individual variation in response. The transdermal route of administration leads to 
lower peak serum 17β-oestradiol concentrations, lower hepatic metabolism and 
more stable steady state profiles compared with the oral route.[20] However, 
transdermal products may be less acceptable to patients. Possibly, the choice of 
oestrogen matters little at the start of pubertal induction where low dosage is of great 
importance. While there is good evidence that puberty can be induced too quickly 
leading to reduced final height, the question whether it can be induced too slowly 
cannot be answered with confidence.[35] Review of the current literature suggests 
that for long-term hormone replacement, oral/transdermal17β-oestradiol needs to be 
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favoured over preparations containing ethinyloestradiol, given their higher 
cardiovascular risk.  
 
Ultimately, the most important requirement is that girls with ovarian insufficiency are 
treated with oestrogen in a timely manner and that treatment is continued through to 
natural menopausal age. Oestradiol deficiency causes cancellous bone loss, 
endothelial dysfunction, reduced insulin production, abnormal lipid patterns, 
increased central adiposity and early atheroma.[5] Hence, it is concerning that at a 
large UK adult Turner clinic, 24% of patients were not receiving oestrogen treatment 
at all at their first clinic attendance.[36], highlighting the importance of treatment 
acceptability, adherence and patient education.  
Finally, there is very little information on specific dose response (breast and uterine 
growth and shape, bone accrual, growth) to oral or transdermal 17β-oestradiol and 
oral ethinyloestradiol, and the bioequivalency of preparations. Estimated daily dose 
equivalence from the current literature (depending on assays and clinical endpoints) 
are: 50/100µg transdermal (applied twice weekly until replaced) = 2mg oral 17β-
oestradiol (per day) = 20µg ethinyloestradiol (per day).[5, 37]  
 
PROPOSED REGIMENS FOR PUBERTAL INDUCTION 
Pubertal induction should be individualised taking the girl’s and family’s views into 
consideration as well as parameters such as height, age, pubertal stage and co-
morbidities. The optimal oestrogen treatment comprising route, drug, and dose 
increments should be determined for each girl. Amongst the paediatric endocrine 
community, there is general agreement that oestrogen starting doses for pubertal 
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induction should be about 10% of adult replacement doses. Following extensive 
literature review, consultation with external experts and the UK Turner Syndrome 
support group, we present below optimised regimens for pubertal induction in girls 
with ovarian insufficiency. All induction regimens will take girls into later pubertal 
stages (Tanner 3-5) over 2.5 years, following which adult hormone replacement 
options should be used.  
 
Transdermal 17β-oestradiol 
The published regimens for pubertal induction using transdermal 17β-oestradiol were 
considered impractical to administer and implement.[4-6] Therefore, a pragmatic 
approach to the transdermal regimen was taken, ensuring the use of low doses of 
17β-oestradiol, particularly in early puberty.[12] (personal communication with M 
Zacharin and T Randell, 2016). 
Regimen using 25µg 17β-oestradiol matrix patch (Table 1) 
Matrix patches are self-adhesive and release approximately 25µg 17β-oestradiol /24 
hours. Since the oestradiol is evenly distributed throughout the patch, the patches 
can be cut to provide the required dose. Practically, patches are cut into ½ or ¼ as 
more complex divisions would be prone to inaccuracies and impracticable. Unused 
patch fractions may be stored in their packaging in the fridge for up to one week. The 
patch (or patch fraction) should be applied to clean dry skin over the buttocks or hips 
using Opsite® (a transparent adhesive film) if necessary to ensure good adhesion.  
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Table 1 Regimen for pubertal induction using 25µg/24h 17β-oestradiol matrix 
patch applied once or twice weekly and left in situ for 3-4 days 
Monday to Thursday Friday to Sunday Duration (months) 
¼ patch No patch 6 
¼ patch ¼ patch 6 
½ patch ¼ patch 6 
½ patch ½ patch 6 
1 patch 1 patch 6 
Progress to adult oestrogen / progestogen replacement therapy  
 
Oral 17β-oestradiol 
Whilst oral 17β-oestradiol is indeed used globally for pubertal induction in various 
preparations, there is a lack of published evidence. Here, we adopt a modification of 
the regimens published by Labarta and Zacharin.[12, 15] 17β-oestradiol is only 
commercially available in 1mg tablets and this regimen involves breaking the 1mg 
tablets (Table 2).  
 
Table 2 Regimen for pubertal induction using 1mg 17β-oestradiol tablets 
Dose Tablets Frequency Equivalent daily 
dose 
Duration (months) 
0.5mg ½ Alternate days 0.25mg 12 
0.5mg ½ Daily 0.5mg 6 
0.5mg/1mg ½, 1 Alternate days 0.75mg 6 
1mg  1 Daily 1mg 6 
Progress to adult oestrogen / progestogen replacement therapy  
 
Girls and young women taking natural 17β-oestradiol for pubertal induction may 
have serum oestradiol levels measured to monitor therapy. Ideally, serum oestradiol 
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levels should be maintained <50pmols/L during the first 18-24 months of pubertal 
induction to accelerate linear growth without rapidly advancing bone maturation.[5] 
However, serum oestradiol levels <60pmols/L are not measurable by most clinical 
laboratory methods. If a girl seems to be making either too slow or too rapid progress 
through puberty, ultra-sensitive oestradiol assays should be employed. Such assays 
are based on liquid chromatography tandem mass spectrometry with limits of 
detection of 4-8pmols/L.[38] 
 
Oral Ethinyloestradiol 
This regimen is derived from Hindmarsh.[22] (Table 3) Ethinyloestradiol is not easily 
measured in serum. 
 
Table 3 Regimen for pubertal induction using 2µg ethinyloestradiol tablets 
Dose (µg) Tablets Frequency Duration (months) 
2 1 Daily 6 
4 2 Daily 6 
6 3 Daily 6 
8 4 Daily 6 
10 5 x 2µg or 1 x 10µg Daily 6 
Progress to adult oestrogen / progestogen replacement therapy 
 
Table 4 provides a summary of the suggested oestrogen replacement regimens for 
pubertal induction 
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Table 4 Summary of the suggested oestrogen regimens 
Months 
from start of 
induction 
25µg 17β-oestradiol 
matrix patch (e.g. 
Evorel® 25) 
17-β-oestradiol 
(Oestradiol 
valerate) 1mg 
tablets 
Ethinyloestradiol 
2 µg tablets 
0 ¼ patch for 3-4 days, no 
patch 3-4 days 
0.5mg (½ tablet) 
alternate days 
2µg (1 tablet) daily 
6 ¼ patch all week 
(change every 3-4 days) 
0.5mg (½ tablet) 
alternate days 
4 µg (2 tablets) daily 
12 ¼ patch for 3-4 days, ½ 
patch for 3-4 days 
0.5mg (½ tablet) 
daily 
6µg (3 tablets) daily 
18 ½ patch all week 
(change every 3-4 days) 
0.5mg and 1mg 
alternate days 
8µg (4 tablets) daily 
24* 1 patch all week 
(change every 3-4 days) 
1mg (1 tablet) daily 10µg (5 tablets) daily 
30* Adult COCP or HRT Adult COCP or 
HRT 
Adult COCP or HRT 
 
* Progestogens should be introduced only after a suitable duration of unopposed 
oestrogen (usually 2-3 years) or if more than one episode of significant breakthrough 
bleeding occurs. 
 
Clinical monitoring of progress for all pubertal induction regimens 
 
To ensure safety and efficacy of the suggested approaches, the following clinical 
data should be collected (Table 5):  
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Table 5 Clinical monitoring of progress for all pubertal induction regimens 
Parameter Pre- 
Puberty 
During puberty  
(every 6/12) 
Post puberty 
Blood Pressure Yes Yes Yes (every 6/12) 
Height velocity (HV) Yes Yes Yes (until HV<2cms/year) 
Pubertal staging Yes Yes No 
Pelvic USS Yes No Yes. Document uterine size and 
shape 
Bone age Yes Yes (annually) No 
Bone density scan No No One year post menarche; in 
case of low size-corrected BMD 
or non-compliance measure 
again in 3-5 years  
 
 
PROGRESSION TO ADULT HORMONE REPLACEMENT THERAPY 
A progestogen will be introduced for all patients for 12-14 days every 1-3 months at 
breakthrough bleeding or after 2.5 years of treatment with oestrogen. The preferred 
progestogen is utrogestan 200mg once daily. Alternatively, medroxyprogesterone 
acetate 5mg daily may be used. Norethisterone 5mg daily is available but is more 
androgenic than the other preparations and is linked to a higher incidence of 
dysmenorrhoea. 
Once a dose of transdermal 17β-oestradiol 25µg/24h, oral 17β-oestradiol 1mg or 
oral ethinyloestradiol 10µg is reached and the girls are receiving a cyclical 
progestogen, there are further options for their longer term management as young 
women. 
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Transdermal / oral 17β-oestradiol 
Transdermal 17β-oestradiol may be continued as a matrix patch or an oestrogen gel 
(e.g. Sandrena®). Adult doses of transdermal oestradiol via patch vary between 50-
100µg/24 hours and adult doses of gel vary between 0.5-1mg oestradiol daily. Some 
young women may prefer oral medication and there are a number of different 
proprietary preparations which provide 1-2mg of oral 17β-oestradiol daily according 
to requirement (e.g. Elleste Solo®).  
Many preparations are produced in user-friendly packs with patches/tablets 
containing oestrogen alone, followed by patches/tablets containing both oestrogen & 
progestogen combined (e.g. Evorel Sequi® [patch], Elleste Duet® [oral]). Many oral 
preparations contain norethisterone as the progestogen but in low doses of 0.5-
1.0mg. Similarly, the dose of medroxyprogesterone acetate is low in these 
preparations (1-2mgs). 
Women wishing to avoid withdrawal bleeds may be given continuous combined 
preparations, either transdermal patches (e.g. Evorel Conti®) or oral tablets (e.g. 
Elleste Duet Conti®). However, women with any residual ovarian function may 
experience troublesome breakthrough bleeding on these preparations. 
In young adult women standard laboratory oestradiol assays are used to monitor 
serum oestradiol levels, aiming for a target 17β-oestradiol level of 350pmol/l.[20] 
Progestogen may also be provided using a levonorgestrel-releasing intrauterine 
device (e.g. Mirena® coil). It is important to ensure that the uterus is of adult 
dimensions (about 7.5 x 5 x 2.5cms) by ultrasound before use and girls who are not 
sexually active may require a brief general anaesthetic for insertion.[39]  
Page 18 of 26
https://mc.manuscriptcentral.com/adc
Archives of Disease in Childhood
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
 
Women with any potential residual ovarian function in whom pregnancy is not 
desired should be counselled about the need for additional contraception if using 
these preparations. 
 
Combined Oral Contraceptive Pill (COCP) 
Advice on the use of the COCP for adult replacement therapy should be guided by a 
risk assessment as set out by the Faculty of Sexual & Reproductive Healthcare.[40] 
The contained oestrogen is usually ethinyloestradiol (e.g. Microgynon30®, 
Marvelon®) although17β-oestradiol is used occasionally (e.g. Qlaira®). In order to 
maximise oestrogen exposure, girls are advised to take at least 3 packs of pills 
“back-to-back” to reduce “oestrogen-free” weeks. This has the additional benefit of 
reducing the frequency of withdrawal bleeds. Preparations can also be taken 
continuously to avoid withdrawal bleeding although initially there may be some 
breakthrough bleeding until the endometrial lining is atrophied. 
The full scope of oestrogen/progestogen replacement for adult women is beyond the 
remit of this guideline. It is anticipated that young women with ovarian insufficiency 
will be reviewed in a Transition clinic alongside an adult Gynaecologist or an adult 
Endocrinologist and kept under review throughout adult life. 
 
CONCLUSION AND RESEARCH NEEDS 
The induction regimens proposed here are based on synthesis of the literature, 
expert views, consultation, pragmatism and practicability. The evidence suggests 
that transdermal 17β-oestradiol has the most favourable efficacy, safety and cost 
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profile. Therefore, this BSPED working group recommends it as first choice for 
pubertal induction in girls.  
Nevertheless, how the essential clinical outcomes (breast and uterine size and 
shape, final height, bone mass, safety and acceptance) compare between regimens 
has not been well studied. The lack of randomised controlled studies on pubertal 
induction in girls needs to be addressed. It is anticipated that prospective collection 
of data from these proposed regimens will provide valuable information about their 
efficacy and acceptability. 
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Pros and Cons of oral/transdermal 17β-oestradiol versus oral 
ethinyloestradiol for pubertal induction in girls 
Pros for oral / transdermal 17β-oestradiol 
• 17β-oestradiol is more physiological than synthetic ethinyloestradiol especially 
when administered transdermally since the first pass hepatic effect is abolished. 
• Observational studies suggest that oral or transdermal 17β-oestradiol is 
effective at inducing puberty. Treatment using transdermal 17β-oestradiol can 
be individualised and can mimic normal puberty closely. 
• Oral 17β-oestradiol tablets and transdermal matrix patches are readily 
available, cheap and have got a favourable cardiovascular risk profile compared 
to ethinyloestradiol. 
Cons for oral / tra sdermal 17β-oestradiol 
• Transdermal patches may be more difficult to use particularly when cutting 
patches to small sizes as they may fall off and require tape support. 
• Transdermal patches may be less acceptable to girls undergoing pubertal 
induction, particularly if the patch becomes visible or they have a reaction to the 
adhesive. 
• There is some suggestion of inter-individual variation in response to oral 17β-
oestradiol tablets and transdermal patches. 
Pros for oral ethinyloestradiol 
• Oral ethinyloestradiol has been used extensively for pubertal induction, 
particularly in the UK & USA. 
• The tablet preparations are acceptable and easy to take. 
• Millions of women worldwide use ethinyloestradiol in the form of the COCP 
which has a good safety profile. 
Cons for oral ethinyloestradiol 
• In recent times, low dose ethinyloestradiol tablets (2 and 10 µg) have escalated 
in cost significantly. They are no longer always readily available. 
• Although effective at inducing puberty, the outcomes may be suboptimal and 
more physiological agents such as 17β-oestradiol may be preferable. 
• Oral ethinyloestradiol is associated with an increased risk of hypertension and 
venous thromboembolism in adults and this risk may be present also in 
children. 
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